Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead compound, AEOL 10150, is entering human clinical trials in oncology where it is used in combination with radiation therapy. AEOL 10150 had been tested in two Phase-I clinical trials. The compound is also being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (pulmonary acute radiation syndrome or Lung-ARS), as well as the gastrointestinal sub-syndrome of acute radiation syndrome (GI-ARS). It is also being developed for use as a countermeasure for exposure to chemical vesicants, such as chlorine gas and sulfur mustard gas. These compounds, known as metalloporphyrins, scavenge reactive oxygen species (ROS) at the cellular level, mimicking the effect of the body�s own natural antioxidant enzyme superoxide dismutase (SOD). Its lead compound, AEOL 10150, is a metalloporphyrin designed to neutralize reactive oxygen and nitrogen species.